Company news
Vir Biotechnology, Inc. (NASDAQ:VIR) news
Vir Biotechnology, Inc. news releases on 6ix. Latest, Oct 5, 2026: Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart…
Press releases & updates
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
October 5, 2026
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
October 4, 2026
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
October 1, 2026
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
September 30, 2026
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 5, 2026
Vir Biotechnology Announces Chief Financial Officer Transition
July 24, 2026
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
July 22, 2026
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
June 10, 2026
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
May 18, 2026
Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 6, 2026
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
May 5, 2026
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
April 23, 2026
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
April 15, 2026
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
April 12, 2026
Vir Biotechnology to Participate in Upcoming Investor Conferences
February 25, 2026
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
February 25, 2026
Vir Biotechnology Announces Proposed Public Offering of Common Stock
February 24, 2026
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
February 23, 2026
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 22, 2026
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
February 22, 2026
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
February 9, 2026
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
January 11, 2026
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
December 17, 2025
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
December 15, 2025
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
November 18, 2025
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
November 8, 2025
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
November 6, 2025
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 4, 2025
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
November 2, 2025
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
October 21, 2025
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
October 8, 2025
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
October 6, 2025
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 24, 2025
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 6, 2025
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
August 5, 2025
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
July 30, 2025
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
July 23, 2025
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
July 21, 2025
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
July 14, 2025
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
May 27, 2025
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
May 19, 2025
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
May 11, 2025
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
May 8, 2025
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 6, 2025
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
April 29, 2025
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
April 23, 2025
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
March 20, 2025